

Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}



{{PANUMCODE}}

## Neulasta and pegfilgrastim biosimilars

### Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at 1-866-814-5506. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to [do\\_not\\_call@cvscaremark.com](mailto:do_not_call@cvscaremark.com). An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} Date: {{TODAY}}  
Patient's ID {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}}  
Physician's Name: {{PHYFIRST}} {{PHYLAST}}  
Specialty: \_\_\_\_\_, NPI#: \_\_\_\_\_  
Physician Office Telephone: {{PHYSICIANPHONE}} Physician Office Fax: {{PHYSICIANFAX}}  
Request Initiated For: {{DRUGNAME}}

1. What is the prescribed drug?  
☐ Neulasta      ☐ Fulphila      ☐ Fylnetra      ☐ Nyvepria  
☐ Stimufend      ☐ Udenyca      ☐ Ziextenzo      ☐ Other, please specify. \_\_\_\_\_
2. What is the patient's diagnosis?  
☐ Neutropenia associated with myelosuppressive anti-cancer therapy  
☐ Hairy cell leukemia  
☐ Hematopoietic subsyndrome of acute radiation syndrome  
☐ Stem cell transplantation-related indication  
☐ Other \_\_\_\_\_
3. What is the ICD-10 code? \_\_\_\_\_

#### Section A: Preferred Product - *Complete this section if Stimufend is prescribed*

4. Coverage for the requested drug is provided when the patient has tried and had a treatment failure with at least three of the formulary medications, or all of the formulary alternatives if there are fewer than three. The formulary alternatives for the requested drug are Fylnetra, Nyvepria and Ziextenzo. Can the patient's treatment be switched to a formulary alternative? ***If Yes, fax a new prescription to the pharmacy and skip to diagnosis section.***  
☐ Yes   ☐ No
5. Has the patient tried and had a documented inadequate response or intolerable adverse reaction to at least three of the formulary medications, or all of the formulary alternatives if there are fewer than three? Note: Formulary medications should be prescribed first unless the patient is unable to use or receive treatment with the alternative.  
☐ Yes   ☐ No   *Formulary alternative(s): Fylnetra, Nyvepria and Ziextenzo*

***If Yes, indicate the formulary alternative and the reason for treatment failure and skip to #7.***

Drug name: \_\_\_\_\_ Reason for treatment failure: \_\_\_\_\_  
Drug name: \_\_\_\_\_ Reason for treatment failure: \_\_\_\_\_  
Drug name: \_\_\_\_\_ Reason for treatment failure: \_\_\_\_\_

**Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Neulasta and pegfilgrastim biosimilars SGM - 9/2023.

**CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081**

**Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • [www.caremark.com](http://www.caremark.com)**

**Member Name:** {{MEMFIRST}} {{MEMLAST}} **DOB:** {{MEMBERDOB}} **PA Number:** {{PANUMBER}}

6. Does the patient have a documented contraindication to all or at least three of the formulary alternatives: Fynetra, Nyvepria, Ziextenzo? ☐ Yes ☐ No

*If Yes, specify the formulary alternative the patient is unable to take and describe the contraindication(s):*

Drug name: \_\_\_\_\_ Contraindication: \_\_\_\_\_

Drug name: \_\_\_\_\_ Contraindication: \_\_\_\_\_

Drug name: \_\_\_\_\_ Contraindication: \_\_\_\_\_

7. Have chart notes or other documentation supporting the inadequate response, intolerable adverse reaction, or contraindication to at least three of the formulary medications, or all of the formulary alternatives if there are fewer than three? **ACTION REQUIRED: Submit chart note(s) or other documentation indicating prior treatment failure, severity of the adverse event (if any), and dosage and duration of the prior treatment, or contraindication to formulary alternatives.** ☐ Yes ☐ No *Skip to diagnosis section.*

Section B: Preferred Product - Complete this section if Fulphila, Neulasta, Nyvepria, or Udenyca are prescribed

8. The preferred products for your patient's health plan are Fynetra, Nyvepria, and Ziextenzo. Can the patient's treatment be switched to a preferred product? **ACTION REQUIRED: If Yes, fax a new prescription to the pharmacy and skip to diagnosis section.** ☐ Yes - Ziextenzo ☐ Yes - Fynetra ☐ Yes - Nyvepria  
☐ No - Continue request for non-preferred product
9. Has the patient had a documented intolerable adverse event to all of the preferred products (Fynetra, Nyvepria, and Ziextenzo)? **ACTION REQUIRED: If Yes, attach supporting chart note(s).** ☐ Yes ☐ No
10. Was the intolerable adverse event an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products)? **ACTION REQUIRED: If No, attach supporting chart note(s).** ☐ Yes ☐ No

**Complete the following section based on the patient's diagnosis, if applicable.**

Section C: Hematopoietic Subsyndrome of Acute Radiation Syndrome

11. Will the requested medication be used for the treatment of radiation-induced myelosuppression following a radiological/nuclear incident? ☐ Yes ☐ No

Section D: Hairy Cell Leukemia

12. Will the requested medication be used for treatment of neutropenic fever following chemotherapy?  
☐ Yes ☐ No

Section E: Neutropenia in Cancer Patients Receiving Myelosuppressive Chemotherapy

13. Will the requested medication be used in combination with any other colony stimulating factor products within any chemotherapy cycle? ☐ Yes ☐ No
14. Will the patient be receiving chemotherapy and radiation therapy at the same time? ☐ Yes ☐ No
15. Will the requested medication be administered with a weekly chemotherapy regimen without breaks?  
☐ Yes ☐ No
16. For which of the following indications is the requested medication being prescribed?  
☐ Primary prophylaxis (i.e., to be given 24 hours after first cycle of chemotherapy) of febrile neutropenia in a patient with a solid tumor or non-myeloid malignancy  
☐ Secondary prophylaxis of febrile neutropenia in a patient with a solid tumor or non-myeloid malignancies, *skip to #20*  
☐ Other \_\_\_\_\_
17. Has the patient received, is currently receiving, or will be receiving myelosuppressive anti-cancer therapy that is expected to result in 20% or higher incidence of febrile neutropenia? **ACTION REQUIRED: If Yes, please submit documentation confirming the patient's diagnosis and the chemotherapeutic regimen and no further questions.** ☐ Yes ☐ No

**Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Neulasta and pegfilgrastim biosimilars SGM - 9/2023.

**CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081**

**Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com**

**Member Name:** {{MEMFIRST}} {{MEMLAST}} **DOB:** {{MEMBERDOB}} **PA Number:** {{PANUMBER}}

18. Has the patient received, is currently receiving, or will be receiving myelosuppressive anti-cancer therapy that is expected to result in 10-19% incidence of febrile neutropenia? ***ACTION REQUIRED: If Yes, please submit documentation confirming the patient's diagnosis and the chemotherapeutic regimen.*** ☐ Yes ☐ No
19. Is the patient considered to be at high risk for febrile neutropenia because of bone marrow compromise or co-morbidity, including any of the following? ***ACTION REQUIRED: If Yes, please submit documentation confirming the patient's risk factors and no further questions.***
- ☐ Yes - Active infections, open wounds, or recent surgery
  - ☐ Yes - Age greater than or equal to 65 years
  - ☐ Yes - Bone marrow involvement by tumor producing cytopenias
  - ☐ Yes - Previous chemotherapy or radiation therapy
  - ☐ Yes - Poor nutritional status
  - ☐ Yes - Poor performance status
  - ☐ Yes - Previous episodes of FN
  - ☐ Yes - Other serious co-morbidities, including renal dysfunction, liver dysfunction, HIV infection, cardiovascular disease
  - ☐ Yes - Persistent neutropenia
  - ☐ No - None of the above
20. Has the patient experienced a febrile neutropenic complication or a dose-limiting neutropenic event (a nadir or day of treatment count impacting the planned dose of chemotherapy) from a prior cycle of similar chemotherapy? ☐ Yes ☐ No
21. For the planned chemotherapy cycle, will the patient receive the same dose and schedule of chemotherapy as the previous cycle (for which primary prophylaxis was not received)? ☐ Yes ☐ No

***I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.***

**X**

**Prescriber or Authorized Signature**

**Date (mm/dd/yy)**

**Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Neulasta and pegfilgrastim biosimilars SGM - 9/2023.

**CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081**

**Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • [www.caremark.com](http://www.caremark.com)**